According to the National Comprehensive Cancer Network (NCCN) guidelines, hormonal therapies including anastrozole (aromatase inhibitor), letrozole (aromatase inhibitor), leuprorelin acetate (gonadotropin-releasing hormone analog), megestrol acetate (synthetic progestin), and tamoxifen (anti-estrogen) are all classified as approved treatments for recurrent forms of epithelial ovarian cancers [72]. This evidence concerns the gene CYP19A1 and ovarian carcinoma.